Refractory Anaemia with Excess Blasts (RAEB) clinical trials at UCSD

• Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

  Sorry, in progress, not accepting new patients

  The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.

  La Jolla, California and other locations

Last updated: June 11, 2021